Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tarsus Pharmaceuticals (TARS) Net Cash Flow: 2020-2025

Historic Net Cash Flow for Tarsus Pharmaceuticals (TARS) over the last 6 years, with Sep 2025 value amounting to $16.1 million.

  • Tarsus Pharmaceuticals' Net Cash Flow rose 429.09% to $16.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.9 million, marking a year-over-year decrease of 20.73%. This contributed to the annual value of -$127.6 million for FY2024, which is 183.22% down from last year.
  • Latest data reveals that Tarsus Pharmaceuticals reported Net Cash Flow of $16.1 million as of Q3 2025, which was up 120.31% from -$79.1 million recorded in Q2 2025.
  • Tarsus Pharmaceuticals' 5-year Net Cash Flow high stood at $119.9 million for Q3 2023, and its period low was -$97.8 million during Q4 2022.
  • Over the past 3 years, Tarsus Pharmaceuticals' median Net Cash Flow value was -$4.9 million (recorded in 2024), while the average stood at $4.0 million.
  • As far as peak fluctuations go, Tarsus Pharmaceuticals' Net Cash Flow surged by 844.60% in 2021, and later plummeted by 4,469.80% in 2024.
  • Quarterly analysis of 5 years shows Tarsus Pharmaceuticals' Net Cash Flow stood at -$12.5 million in 2021, then plummeted by 684.58% to -$97.8 million in 2022, then surged by 98.24% to -$1.7 million in 2023, then tumbled by 4,469.80% to -$78.8 million in 2024, then skyrocketed by 429.09% to $16.1 million in 2025.
  • Its last three reported values are $16.1 million in Q3 2025, -$79.1 million for Q2 2025, and $81.0 million during Q1 2025.